Abstract | BACKGROUND: METHODS: In this prospective, double-blind, randomized, placebo-controlled 3-arm trial of 121 HIV-infected participants on suppressive ART for >48 weeks, we evaluated the effects of 12 weeks of daily aspirin 100 mg, aspirin 300 mg, or placebo on soluble and cellular immune activation markers, flow-mediated dilation (FMD) of the brachial artery, and serum thromboxane B2, a direct readout of platelet COX-1 inhibition. RESULTS: The 300-mg and 100-mg aspirin arms did not differ from placebo in effects on soluble CD14, interleukin (IL)-6, soluble CD163, D-dimer, T-cell or monocyte activation, or the other immunologic endpoints measured. Endothelial function, as measured by FMD, also was not significantly changed when comparing the 300-mg and 100-mg aspirin arms to placebo. CONCLUSIONS:
Aspirin treatment for 12 weeks does not have a major impact on soluble CD14, IL-6, soluble CD163, D-dimer, T-cell or monocyte activation, or FMD, suggesting that inhibition of COX-1-mediated platelet activation does not significantly improve HIV-related immune activation and endothelial dysfunction. Although future studies are needed to further identify the causes and consequences of platelet activation in ART-treated HIV infection, interventions other than COX-1 inhibition will need to be explored to directly reduce immune activation in treated HIV infection.
|
Authors | Meagan P O'Brien, Peter W Hunt, Douglas W Kitch, Karin Klingman, James H Stein, Nicholas T Funderburg, Jeffrey S Berger, Pablo Tebas, Brian Clagett, Daniela Moisi, Netanya S Utay, Fran Aweeka, Judith A Aberg |
Journal | Open forum infectious diseases
(Open Forum Infect Dis)
Vol. 4
Issue 1
Pg. ofw278
( 2017)
ISSN: 2328-8957 [Print] United States |
PMID | 28480270
(Publication Type: Journal Article)
|
Copyright | © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |